• Novel Assay Platform for 3D Microfluidic Cancer Research
    Top left: ONCO-Chip 3D microfluidic plate. Top right: time sequence showing CAR-T cells interacting with 3D tumour models. Bottom: schematic and microscopy images of CAR-T killing cancer cells only (unlabelled) in different combination treatments.
  • Custom CAR-T development by AMSBIO.

Laboratory Products

Novel Assay Platform for 3D Microfluidic Cancer Research

Oct 12 2021

Chimeric antigen receptor (CAR-T) cells are genetically modified T-cells that are engineered to find and kill cancer cells by targeting specific cancer-associated proteins, or antigens. CAR-T cell therapy is highly effective against haematological malignancies, but faces challenges in solid tumours due to the immunosuppressive effects of the tumour microenvironment. Often, combination therapies, such chemotherapy and checkpoint blockage, are used with CAR-T to improve efficacy.

The University of Strathclyde (UoS) in Glasgow, and ScreenIn3D Ltd, are using custom CAR-T products supplied by AMSBIO to perform novel immune-oncology assays in 3D microfluidic cancer models.


To investigate CAR-T efficacy, their off-target cytotoxicity and synergistic effects when used in combination assays, UoS and ScreenIn3D researchers developed novel miniaturised screening assays that use very small amounts of CAR-T cells in 3D complex in vitro models of solid tumours on a chip.


This exciting technological advance by UoS and ScreenIn3D researchers is described in detail in a recently published technical article: https://bit.ly/3iASDy0

AMSBIO offers a custom service that enables researchers to take advantage of the astonishing clinical breakthroughs achieved with CAR-T cells in various haematological malignancies. Drawing upon its expertise in monoclonal antibody development (rabbit and mouse), AMSBIO can help you design, plan and execute your CAR-T study, whether you are in the preclinical, clinical or proof of concept stage. The AMSBIO CAR-T platform is highly adaptable to your needs and starting materials, allowing you to start with a target molecule (Phase I) or antibody (Phase II). As part of their custom CAR-T development service, AMSBIO construct the single chain variable fragment (ScFv), transfer it into a CAR lentivector of your choice, make lentivirus and transduce activated human (or mouse) T cells. After the CAR-T cells proliferate, the cytotoxicity is measured in a real time assay, CAR expression analysed and cytokine production quantified.

More information online


Digital Edition

LabAsia Buyers Guide 2021

October 2021

In this Edition Articles - Applications of Newly Developed 2.7 μm Porous Graphitic Carbon Particles in U/HPLC - Improve sensitivity and decrease matrix effects in pesticide residue analysis...

View all digital editions

Events

ASMS Conference - NEW DATES

Oct 31 2021 Philadelphia, PA, USA

analytica Lab Africa -CANCELLED

Nov 02 2021 Johannesburg, South Africa

Lab Innovations 2021

Nov 03 2021 Birmingham, UK

ISPPP 2021

Nov 07 2021 Porto, Portugal

JASIS 2021

Nov 08 2021 Chiba, Japan

View all events